Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

Citation

  • Authors: Du Y. et al.
  • Year: 2022
  • Journal: Thorax
  • Applications: in vitro / DNA / PEIpro
  • Cell type: HEK-293T
    Description: Human embryonic kidney Fibroblast
    Known as: HEK293T, 293T

Method

rSIV.F/HN: recombinant Simian Immunodeficiency Virus (SIV) pseudotyped with the Fusion (F) and Haemagglutinin-Neuraminidase (HN) surface glycoproteins from Sendai virus. S-LV: a SARS-CoV-2 pseudovirus created from a recombinant HIV1 lentiviral vector pseudotyped with the D614G derivative of the SARS-CoV-2 Spike (S) protein The production of rAAV, rSIV.F/HN and S-LV vectors was performed by cotransfection of HEK-293T cells with genome and packaging plasmids using (rAAV) Polyethylenimine (PEI, PolySciences) or (rSIV.F/HN and SLV) PEIpro® (Polyplus). All rSIV vectors were pseudotyped with the F and HN proteins of Sendai virus as described previously. The S-LV (rHIV.Spike.G614+∆19aa.CMV) vector was pseudotyped with the SARS-CoV-2 Spike protein Wuhan sequence (GenBank accession: 43740568) modified by inclusion of a D614G mutation and removal of the 19 C-terminal amino acids. Vectors were purified by (rAAV) discontinuous Iodixanol gradient ultracentrifugation 7 or (rSIV.F/HN, S-LV) anion exchange chromatography and tangential flow filtration. Physical titre (genome copies/mL: GC/mL) of rAAV vectors was determined by quantitative polymerase chain reaction (qPCR) analysis with primers and a probe against WPRE 8. Functional titre of rSIV.F/HN vectors (transducing units/mL: TU/mL) was determined using the same primer/probes on DNA extracted following transduction of HEK-293F cells with dilutions of vector preparations Physical titre (ng p24) of S-LV particles was determined using a p24 immunoassay

Abstract

Background: The COVID-19 pandemic continues to be a worldwide threat and effective antiviral drugs and vaccines are being developed in a joint global effort. However, some elderly and immune-compromised populations are unable to raise an effective immune response against traditional vaccines. Aims: We hypothesised that passive immunity engineered by the in vivo expression of anti-SARS-CoV-2 monoclonal antibodies (mAbs), an approach termed vectored-immunoprophylaxis (VIP), could offer sustained protection against COVID-19 in all populations irrespective of their immune status or age. Methods: We developed three key reagents to evaluate VIP for SARS-CoV-2: (i) we engineered standard laboratory mice to express human ACE2 via rAAV9 in vivo gene transfer, to allow in vivo assessment of SARS-CoV-2 infection, (ii) to simplify in vivo challenge studies, we generated SARS-CoV-2 Spike protein pseudotyped lentiviral vectors as a simple mimic of authentic SARS-CoV-2 that could be used under standard laboratory containment conditions and (iii) we developed in vivo gene transfer vectors to express anti-SARS-CoV-2 mAbs. Conclusions: A single intranasal dose of rAAV9 or rSIV.F/HN vectors expressing anti-SARS-CoV-2 mAbs significantly reduced SARS-CoV-2 mimic infection in the lower respiratory tract of hACE2-expressing mice. If translated, the VIP approach could potentially offer a highly effective, long-term protection against COVID-19 for highly vulnerable populations; especially immune-deficient/senescent individuals, who fail to respond to conventional SARS-CoV-2 vaccines. The in vivo expression of multiple anti-SARS-CoV-2 mAbs could enhance protection and prevent rapid mutational escape.

Go to